Martin Heidecker, PhD

Dr. Heidecker joined Boehringer Ingelheim Venture Fund in 2010 in Germany and moved to Boston, MA in 2013 to open US offices for the fund. He served as board member of ArmaGen Technologies, Inc. and of Tilos Therapeutics, which was acquired by Merck in June 2019. Currently, he serves as board member of Sentien Biotechnologies in Lexington, Abexxa Biologics in Arlington, Libra Therapeutics in San Diego, Rgenta Therapeutics in Cambridge, and TigaTx in Cambridge.